Audit: QRS - Yoga Nidra for Health & Longevity
Audit conducted on 03/09/2026 02:09 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: at-a-glance to ER Conclusion (494–496), protocol cells to ER 366/368/374, time-to-effect to ER 421, benefit and risk tiers to ER 149–239 and 261–301, gates to ER 321–342, monitoring table to ER 455–466, cadence to ER 453, qualitative items to ER 470–474. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedged framings are carried across: “no added benefit over an active alternative” (line 634), “No established target” for HRV (line 690), and the Speculative tiers for both benefits and risks retain the ER’s untested items. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications and cautions remain cautions; the at-a-glance keeps both the “easily beats doing nothing” and the “often fails to beat another structured relaxation technique” halves of ER 498. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | The Contraindications gate draws only on the ER’s “Populations who should avoid Yoga Nidra” list (ER 337–342); the Key Interactions gate draws only on the ER’s eight interaction bullets (ER 321–335). Nothing from Benefit- or Risk-Modifying Factors is promoted into a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers or expert names appear. The only named entities are generic drug and supplement names (lines 596–607), all present in the ER’s own interaction bullets. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No institution, author, lineage or platform is named anywhere in the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Detached, evidence-first register matching the ER, including its scepticism about active-comparator results. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | The at-a-glance leads with the practical upside (free, no equipment, no physical capacity needed) while stating the limits plainly. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as observed ranges and measured targets, never as instruction to the reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; gate items are stated as conditions, not directives. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol and monitoring cells report what trials used and what was measured. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the load-bearing ones (savasana, orthostatic hypotension, obstructive sleep apnoea); savasana is immediately glossed as “Lying flat on the back, legs apart and palms up” (line 486). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Tier lists are semicolon-separated key facts; gate items carry no rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring targets are functional-optimal (110–120/70–75 mm Hg, HbA1c 4.8–5.3%), not conventional treatment thresholds. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Daily-to-five-weekly practice over three to six months and a ten-marker monitoring panel are presented without hedging about burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes home blood-pressure logging, HRV tracking, salivary cortisol and lab panels. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance surfaces the audience-critical caveat that the practice often fails to beat another structured relaxation technique — the decisive signal for readers who already run one. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears in the title and header; “anti-aging” appears nowhere. The speculative benefit is worded “slowed biological aging” (line 567). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Terminology is clinical throughout (“antihypertensives”, “sedative-hypnotics”, “orthostatic hypotension”, “glycated haemoglobin”); the few register-softening phrases (“rest-and-digest”, “average blood sugar”) are carried verbatim from the ER’s own biomarker table. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All verified byte-identical to the template: lines 446, 494, 543, 622, 648, 808, 576, 593, tier labels at 547/553/559/566 and 625/628/632/639, and column headers at 652–654. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 69 data-qrs-var spans present, covering every template name: page_title, header_topic/subline_date/subline_model, at_a_glance, action_1–3 × label/value/sub, time_1–3 × label/value/sub, benefits and risks × 4 tiers, stop_items, caution_items, marker_1–10 × name/target/why, monitoring_cadence, qualitative_item_1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-variable <span website="evidence_review">, <span website="audit"> and <span website="full_review"> hooks (lines 423, 426, 440) are unchanged, as are the stylesheet link, the footer disclaimer and all template comments. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section mapped into the QRS is empty. The ER’s High-risk tier is not an empty state but a reasoned statement (“No risk reaches High: …”, ER 263); its handling is governed by item 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Session length”, “Frequency” and “Posture” (lines 450, 465, 482) match the ER’s bold bullet labels at ER 366, 368, 374 verbatim; monitoring row labels reproduce the ER biomarker names exactly. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | The three Time-to-Effect labels are the outcome names taken from the ER’s own High-tier benefit headings (“Reduced Anxiety and Perceived Stress”, “Lower Resting Blood Pressure”, “Improved Subjective Sleep Quality”, ER 151/157/163), not invented terms. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur in the file; tiering is carried by the <strong> labels and the card colour rules. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | No section or card was added beyond the template. Content is condensed rather than expanded: the ER’s fourth biomarker column (Context/Notes) is dropped entirely, gate rationales are stripped, and the HRV target is shortened from the ER’s wording. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1 and before the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or any card. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because the value contains a colon. All other values are bare and untrimmed of nothing. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: yoga_nidra_2026-0903-0001_Opus_ER.md, matching the ER’s own filename field (ER 17). |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0903-0156 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, with no context-window or other qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: yoga_nidra_2026-0903-0001_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including the appended git_user and git_issue fields; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Yoga Nidra for Health & Longevity - Quick Reference Sheet” — matches ER canonical_topic (ER 8) with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Yoga Nidra for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/03/2026”, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0903-0156. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, identical to the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) carries only the title and the template’s fixed subline; the ER’s “Also known as” line (ER 30) was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 434–438 compress ER 494–498 into cost/dose/equipment, the two firmest outcomes, the active-comparator limit, and where harm concentrates. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “costs nothing, takes ten to thirty minutes, demands no equipment or physical capacity” → ER 494; firmest findings and “sleep close behind” → ER 496; “easily beats doing nothing … fails to beat another structured relaxation technique” → ER 498; “Harms are mild … unresolved trauma” → ER 496. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Wholly plain-language: “guided lying-down practice”, “self-reported anxiety and stress”, “structured relaxation technique”. No acronym appears. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study, author, year or sample size is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result appears; the only figures are the session-length range. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All four items come from the “Populations who should avoid Yoga Nidra” list at ER 337–342. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Lines 579–588 reproduce all four ER avoid-list entries with none added or omitted. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four discrete <li> elements inside the span at lines 578–589. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “where …” rationale clause is stripped: ER’s “where sustained inward attention and imagery can worsen disorganised thinking” and “where extended supine time without treatment risks repeated breathing pauses” are both gone. No dash-trailing clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “current dissociative symptoms” and the supervision exception are kept (lines 581–582); the 20 mm Hg systolic threshold and the “until the transition out of lying flat is managed” window are kept (lines 585–586); “Untreated moderate-to-severe” staging is kept (line 588). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid list uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER does identify four such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one onto the ER’s interaction bullets at ER 321–335. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eight interaction bullets carried across; none duplicates an entry in the Contraindications gate. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements at lines 596–612. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to the agent class plus its example list; the ER’s “Caution, additive” / “Monitor” verdicts and all mechanism and dose-adjustment sentences (ER 321–335) are stripped, as are the in-paren explanatory glosses after the em-dashes. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example list survives intact: amlodipine/lisinopril/losartan/hydrochlorothiazide, zolpidem/temazepam/lorazepam, glipizide/glimepiride, diphenhydramine/doxylamine, melatonin/valerian/magnesium glycinate/ashwagandha, beetroot or dietary nitrate/hibiscus/potassium/magnesium, and the four named behavioural interventions. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER identifies eight such interactions, and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets at ER 366, 368 and 374. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Session length, frequency and posture are the three parameters that define how a session is actually performed; the remaining ER bullets (attribution, competing lineages, genetic polymorphisms, sex-based differences) are contextual rather than actionable. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well more than three actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated (lines 450–489): the trial-length list and the 11-vs-30-minute head-to-head, the daily-to-five-weekly range with its cardiac/hormonal and mental-health windows, and the savasana description with the seated substitute. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Anxiety/perceived stress, resting blood pressure and subjective sleep quality — precisely the three outcomes covered by the ER’s “Time to effect” bullet at ER 421, and the ER’s three High-tier benefits. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order (anxiety → blood pressure → sleep) follows the ER Conclusion’s explicit ranking at ER 496: “The firmest findings are lower blood pressure and lower self-reported anxiety and stress … with sleep close behind”. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated (lines 500–535); “2–4 weeks” and “First session; 1–3 months” both trace directly to ER 421. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 421), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All fifteen entries correspond to the fifteen ER benefit headings at ER 151–239. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated (lines 545–569), each with its fixed tier label. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare benefit name; every ER “Magnitude” line (Hedges’ g values, mm Hg reductions, p-values, sample sizes) is stripped, as is the ER’s “⚠️ Conflicted” marker. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items (3 High, 4 Medium, 5 Low, 3 Speculative), so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six entries correspond to the ER risk headings at ER 267–301. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (lines 624–642). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare risk name; the ER’s prevalence figures (83%, 37%, 8.3%, 25.6%) and the “Not quantified in available studies” magnitude lines are all stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risk span; the ER’s inline gloss “(feeling detached from the body)” (ER 277) is correctly dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records that no risk reaches High (ER 263), and [risks_high] carries style="display: none" at line 624 with no empty-state text substituted. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER biomarker table at ER 455–466, and the cadence line reproduces ER 453. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarkers present in ER order: home blood pressure, resting heart rate, heart rate variability, Pittsburgh Sleep Quality Index, Insomnia Severity Index, morning salivary cortisol, high-sensitivity C-reactive protein, glycated haemoglobin, fasting glucose, thyroid-stimulating hormone. Targets and rationales match the ER verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 799–801 carry the full three-part cadence (blood pressure weekly then monthly; questionnaires at four and twelve weeks then six-monthly; blood tests at three months then six-to-twelve-monthly), matching ER 453. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the “Qualitative markers worth tracking alongside the numbers” list at ER 468–474. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present verbatim in ER order at lines 811–833; none omitted or added. |
Issues 03/09/2026 02:09
Pass rate 100.00%. No issues found.
Issues 03/09/2026 02:02
- 4.2 / 9.5 — Alcohol parenthetical dropped: The fourth Key Interactions item (QRS line 599) reduces the ER bold label “Alcohol and cannabis (over-the-counter and recreational):” (ER line 327) to bare “Alcohol and cannabis”, dropping the parenthetical qualifier entirely instead of preserving it in shortened form; the other seven caution items all retain theirs.
Fixes 03/09/2026 02:02
- 4.2 / 9.5 — Alcohol parenthetical restored: Changed the fourth Key Interactions item from “Alcohol and cannabis” to “Alcohol and cannabis (over-the-counter and recreational)”, restoring the parenthetical qualifier from the ER bold label.